Afuco™ Anti-Human HIV V3 ADCC Recombinant Antibody (KD-247), ADCC Enhanced (CAT#: AFC-342CL)

Figure 1 KD-247 efficiently protects monkeys from pathogenic virus challenge.

A total of 12 cynomolgus monkeys were used for virus challenge studies with SHIV C2/1. In the first group, five monkeys were intravenously inoculated with various doses of KD-247, followed by 20 TCID50s of SHIV C2/1 challenge 24 h after antibody transfer. Monkeys in the second and third groups were injected prior to virus challenge with either 45 mg/kg of normal human immunoglobulin (two monkeys) or saline alone (five monkeys). The following parameters were measured in monkeys given KD-247: (a) concentration of KD-247 in plasma following passive transfer, (b) CD4+-T-cell counts, (c) plasma viremia, (d) Western blot analysis using an HIV-2 Western blot kit (Diagnostics Pasteur, Marnes-La-Coquette, France) (6) of serum samples obtained at autopsy from monkeys given a single high dose (45 mg/kg) of KD-247 (monkeys 4092 and 4099) or NHIgG controls (monkeys 3967 and 3974), and (e) CD95 antigen expression on PBMCs from monkeys challenged with SHIV.

Eda, Y., Murakami, T., Ami, Y., Nakasone, T., Takizawa, M., Someya, K., ... & Higuchi, H. (2006). Anti-V3 humanized antibody KD-247 effectively suppresses ex vivo generation of human immunodeficiency virus type 1 and affords sterile protection of monkeys against a heterologous simian/human immunodeficiency virus infection. Journal of virology, 80(11), 5563-5570.

Figure 2 Neutralization assay of HIV-1 Env pseudotyped virus on TZM-bl cells.

A total of 10 nM maraviroc (CCR5 antagonist) or 5 μM KD-247 Fab or His-tagged scFv variants were preincubated with HIV-1 (JR-FL) Env pseudotyped HIV-1 before infection of TZM-bl. Luminescence was measured 48 h after infection to determine scFv variants that result in>50% neutralization of pseudotyped virus.

Kirby, K. A., Ong, Y. T., Hachiya, A., Laughlin, T. G., Chiang, L. A., Pan, Y., ... & Quinn, T. P. (2014). Structural basis of clade-specific HIV-1 neutralization by humanized anti-V3 monoclonal antibody KD-247. The FASEB Journal, 29(1), 70-80.